Stay updated on SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial
Sign up to get notified when there's something new on the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page.

Latest updates to the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedCore content updated to v3.2.0 with a government-operating-status notice and a removal of the previous v3.1.0 marker.SummaryDifference3%

- Check25 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check40 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2; Back to Top removed.SummaryDifference0.2%

- Check47 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%

- Check54 days agoChange DetectedThe web page has been updated to include new publications related to pembrolizumab and neoplastic processes, while several location-related terms and some previous content about lung cancer and immunological agents have been removed.SummaryDifference8%

- Check68 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%

Stay in the know with updates to SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page.